SCHEMBL9948445

SCHEMBL9948445

Cc1cc(C)nc(N2CCC3(CC2)OCCO3)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 6/20 0.47
HSD17B10 Q99714 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 3/20 0.47
MEN1 O00255 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
HRH4 Q9H3N8 1/20 0.44
USP2 O75604 1/20 0.44
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 1/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
LMNA P02545 2/20 0.41
HCRTR1 O43613 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9949032 0.87 SLC6A2 (0.49) KMT2AALDH1A1HSD17B10HPGDMEN1
SCHEMBL7014268 0.83 HSD17B10 (0.45) KMT2AALDH1A1HSD17B10KDM4EHPGD
SCHEMBL9086580 0.79 TACR2 (0.44) KMT2AALDH1A1HSD17B10KDM4EHPGD
SCHEMBL22041676 0.78 RET (0.55) ALDH1A1MAPTLMNA
SCHEMBL22148549 0.77 KMT2A (0.53) KMT2AALDH1A1HSD17B10KDM4EHPGD
SCHEMBL1707681 0.76 KMT2A (0.79) KMT2AALDH1A1HSD17B10MEN1NPSR1
SCHEMBL22148753 0.75 KMT2A (0.51) KMT2AALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4557553 0.75 TACR2 (0.40) KMT2AALDH1A1HSD17B10KDM4EHPGD
SCHEMBL6987180 0.75 PTPN11 (0.42) ALDH1A1HRH4MAPTSMN1; SMN2
SCHEMBL9082620 0.74 CASP1 (0.61) KMT2AALDH1A1HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes TACR2, TACR1, AGTR1 KMT2A 1555/4885ALDH1A1 44/4885HSD17B10 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.